Myriad Genetics Inc (MYD) – aksjekurser og nyheter

Symboler Symboler	Pris	Endring	Endring (%)	Trend	Forrige pris ved stengetid	Åpne	Høy	Lav	Volum	Markedsverdi
SIXB Materials SIXB Materials	SIXB −0,89%	1 083,04	−9,76	−0,89%	—	1 092,80	1 093,68	1 094,85	1 081,97	—	—
SIXC Communications SIXC Communications	SIXC −0,39%	602,38	−2,36	−0,39%	—	604,74	604,74	605,10	601,34	—	—
SIXE Energy SIXE Energy	SIXE +2,31%	1 242,83	+28,03	+2,31%	—	1 214,80	1 220,81	1 243,82	1 220,81	—	—
SIXI Industrials SIXI Industrials	SIXI −0,62%	1 713,82	−10,75	−0,62%	—	1 724,57	1 727,02	1 732,30	1 707,43	—	—
SIXM Financials SIXM Financials	SIXM +0,09%	639,99	+0,56	+0,09%	—	639,43	641,58	644,53	637,50	—	—
SIXR Staples SIXR Staples	SIXR −0,20%	837,46	−1,69	−0,20%	—	839,15	836,90	840,48	832,89	—	—
SIXRE Real estate SIXRE Real estate	SIXRE −0,65%	214,22	−1,40	−0,65%	—	215,62	215,62	216,21	213,48	—	—
SIXT Technology SIXT Technology	SIXT +0,78%	3 204,38	+24,86	+0,78%	—	3 179,52	3 191,50	3 205,09	3 177,75	—	—
SIXU Utilities SIXU Utilities	SIXU −1,23%	925,38	−11,53	−1,23%	—	936,91	935,42	937,17	923,20	—	—
SIXV Health care SIXV Health care	SIXV −0,69%	1 442,71	−10,06	−0,69%	—	1 452,77	1 445,93	1 447,43	1 434,91	—	—
SIXY Discretionary SIXY Discretionary	SIXY −0,16%	2 361,34	−3,84	−0,16%	—	2 365,18	2 353,64	2 368,10	2 347,80	—	—

MYD:FRA

Myriad Genetics Inc

4,08 €

+0,39%

(+0,016) 1 D

29. apr., 22:00:00 GMT+2 · EUR

Alle symboler

1 D

5 D

1 M

6 M

I år

1 Å

5 Å

MAKS

	Symbol	Pris	Endring	Endring (%)

Genererer viktig statistikk for MYD …

Åpne

4,08 €

Høy

4,08 €

Lav

4,08 €

Markedsverdi

441,99 mill.

Snittvolum

376,00

Volum

0,00

52 u høy

7,10 €

52 u lav

3,30 €

Antall ansatte

Nyhetssaker

Fra kilder på nettet

Yahoo Finance

for 1 døgn siden

Myriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026

Profil

Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new products that assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to a particular drug therapy, assess a patient's risk of disease progression and disease recurrence, and measure disease activity. Wikipedia

Om Myriad Genetics Inc

Administrerende direktørPaul J. Diaz | Paul J. Diaz

Ansatte2,7k

Grunnlagt1991

HovedkontorSalt Lake City, Utah, USA

Sektor-

Nettstedmyriad.com

Alle verdier i USD	mars 2025	juni 2025	sep. 2025	des. 2025
Inntekt	195,90 mill.	213,10 mill.	205,70 mill.	209,80 mill.
Varekostnad	61,70 mill.	61,30 mill.	61,90 mill.	63,00 mill.
Direkte driftskostnader	61,70 mill.	61,30 mill.	61,90 mill.	63,00 mill.
Utgifter til forskning og utvikling	27,50 mill.	25,60 mill.	28,20 mill.	25,50 mill.
Totale kostnader til forskning og utvikling	-	-	-	-
Salgskostnader, generelle kostnader og administrative kostnader	135,70 mill.	138,70 mill.	138,90 mill.	124,30 mill.
Driftskostnader	163,20 mill.	164,30 mill.	167,10 mill.	149,80 mill.
Totale driftskostnader	224,90 mill.	225,60 mill.	229,00 mill.	212,80 mill.
Driftsinntekter	−29,00 mill.	−12,50 mill.	−23,30 mill.	−3,00 mill.
Andre ikke-operasjonelle inntekter	100,00k	−100,00k	400,00k	400,00k
EBT inkludert uvanlige elementer	−29,40 mill.	−330,60 mill.	−26,20 mill.	−8,90 mill.
EBT uten uvanlige elementer	−29,40 mill.	−13,90 mill.	−26,20 mill.	−6,20 mill.
Kostnad for inntektsskatt	−29,30 mill.	−100,00k	1,20 mill.	−1,00 mill.
Faktisk avgiftssats	99,66 %	0,03 %	−4,58 %	11,24 %
Andre driftskostnader	-	-	-	-
Nettoinntekt	−100,00k	−330,50 mill.	−27,40 mill.	−7,90 mill.
Netto fortjenestemargin	−0,05 %	−155,09 %	−13,32 %	−3,77 %
Resultat per aksje	−0,03	0,05	-	0,04
Rente- og investeringsinntekter	300,00k	200,00k	500,00k	800,00k
Rentekostnader	−800,00k	−1,50 mill.	−3,80 mill.	−4,40 mill.
Netto rentekostnader	−500,00k	−1,30 mill.	−3,30 mill.	−3,60 mill.
Avskrivnings- og amortiseringskostnader	-	-	-	-
EBITDA	−14,60 mill.	1,60 mill.	−10,70 mill.	9,60 mill.
Gevinst eller tap ved salg av eiendeler	-	-	-	-

AI-innhold kan inneholde feil. Finn ut mer

HjelpSend tilbakemeldingPersonvern Vilkår Ansvarsfraskrivelse

Finance

Utforskning